ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

socazolimab

Also written as “ZKAB001 5mg/kg”, “ZKAB001 10mg/kg” and “ZKAB001 15mg/kg”.

Its studies are mostly in Uterine Cervical Neoplasms · Osteosarcoma · Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Melanoma, led by 2 companies.

Drug pageSocazolimab: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 21, 20209 company-led studies, 2 open or runningNext primary completion: Sep 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lee's Pharmaceuticalits history only81 open or runningphase 3since Apr 21, 2020Sep 12, 2018Sep 1, 2027phase 3 · NCT06459687
Suzhou BlueHorse Therapeutics11 open or runningphase 2since Feb 26, 2026Feb 26, 2026Dec 31, 2027phase 2 · NCT07444437

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Suzhou BlueHorse Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2021Named socazolimabINNProposed as its International Nonproprietary Name in WHO's List 125
  2. Feb 26, 2026First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07444437 · 45 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07444437

TargetBeta

CD274 →read by rule
“A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

The one study Suzhou BlueHorse Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07444437Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 31, 202745

How it is read

Names in the registry

  • “ZKAB001 5mg/kg”, 4 entries
  • “ZKAB001 10mg/kg”, 3 entries
  • “ZKAB001 15mg/kg”, 3 entries
  • “PD-1 / PD-L1 monoclonal antibody”, 1 entry
  • “Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.